BLINKLAB LIMITED — Share Issue/Capital Change 2026

Apr 15, 2026

Appendix 3B - Proposed issue of securities

Update Summary

Entity name
BLINKLAB LIMITED

Announcement Type
Update to previous announcement

Date of this announcement
16/4/2026

Reason for update to a previous announcement
Actual acceptance amendment.

Refer to next page for full details of the announcement

Appendix 3B - Proposed issue of securities
1 / 6

---

Appendix 3B - Proposed issue of securities

Part 1 - Entity and announcement details

1.1 Name of +Entity

BLINKLAB LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ACN

Registration Number

652901703

1.3 ASX issuer code

BB1

1.4 The announcement is

Update/amendment to previous announcement

1.4a Reason for update to a previous announcement

Actual acceptance amendment.

1.4b Date of previous announcement to this update

16/4/2026

1.5 Date of this announcement

16/4/2026

1.6 The Proposed issue is:

A placement or other type of issue

Appendix 3B - Proposed issue of securities

---

Appendix 3B - Proposed issue of securities

Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?
Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	11/6/2026	Estimated

Comments
Shareholder approval required for director participation in the Placement and for joint lead manager options.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?
Existing class

Will the proposed issue of this +security include an offer of attaching +securities?
No

Details of +securities proposed to be issued

ASX +security code and description
BB1: ORDINARY FULLY PAID

Number of +securities proposed to be issued
27,230,769

Reason for the update of 'Number of +securities proposed to be issued'

Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
Yes

In what currency is the cash consideration being paid?
AUD - Australian Dollar

What is the issue price per +security?
AUD 0.65000

Appendix 3B - Proposed issue of securities

---

Appendix 3B - Proposed issue of securities

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?
New class

Will the proposed issue of this +security include an offer of attaching +securities?
No

Details of +securities proposed to be issued

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

Have you received confirmation from ASX that the terms of the proposed +securities are appropriate and equitable under listing rule 6.1?
No

Will the entity be seeking quotation of the 'new' class of +securities on ASX?
No

ASX +security code	+Security description
New class-code to be confirmed	Unlisted - JLM Options @ $0.975, expiring 30 June 2028.

+Security type
Options

Number of +securities proposed to be issued
5,446,154

Reason for the update of 'Number of +securities proposed to be issued'
[blank]

Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
No

Please describe the consideration being provided for the +securities
Fee for service

Please provide an estimate of the AUD equivalent of the consideration being provided for the +securities
0.000010

Will all the +securities issued in this class rank equally in all respects from their issue date?
Yes

Appendix 3B - Proposed issue of securities

---

Appendix 3B - Proposed issue of securities

Options details

+Security currency	Exercise price	Expiry date
AUD - Australian Dollar	AUD 0.9750	30/6/2028

Details of the type of +security that will be issued if the option is exercised

BB1 : ORDINARY FULLY PAID

Number of securities that will be issued if the option is exercised

One fully paid ordinary share (ASX: BB1)

Please provide a URL link for a document lodged with ASX setting out the material terms of the +securities proposed to be issued or provide the information by separate announcement.

Part 7C - Timetable

7C.1 Proposed +issue date

23/4/2026

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1? Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

14,964,675

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)? Yes

7D.1c (i) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?

12,000,000

7D.1c (ii) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase plan in which existing ordinary +security holders would have been eligible to participate

Most appropriate mechanism at present.

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? No

Appendix 3B - Proposed issue of securities

---

Appendix 3B - Proposed issue of securities

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?
Yes

7E.1a Who is the lead manager/broker?
Morgans Corporate, Westar Capital and Alpine Capital acted as Joint Lead Managers for the Placement.

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?
The JLM will receive 7% of gross funds raised under the Placement and approximately one option for every 5 New Shares issued under the Placement, with an exercise price of A$0.975 per option and expiry of 30 June 2028. Both cash fees and options will be split equally between each of the JLM. The issue of options to the JLM is subject to shareholder approval at the GM of shareholders proposed for mid-June 2026.

7E.2 Is the proposed issue to be underwritten?
No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities
See ASX announcement today for use of funds. Includes, support completion of ongoing FDA 510(k) registrational trial for autism diagnosis using BB1 Dx1 platform. Support CE and MDR approval processes for BB1 Dx1 in Europe (diagnostic tool for autism).

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?
No

7F.2 Any other information the entity wishes to provide about the proposed issue

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

Appendix 3B - Proposed issue of securities